Gerami Seitzman is an Ophthalmology physician affiliated with University of California, San Francisco. OpenAlex indexes 121 publications with 1,663 citations (h-index 23); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
490 Illinois St
San Francisco, CA 941582510
Telephone
415-514-8200Provider last certified this registry record 8 Mar 2021.
Clinical trials
- Study for Remote Investigation of Evaporative Dry Eye Disease
Sponsor: University of California, San Francisco
- Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
Sponsor: University of California, San Francisco
- Parasitic Ulcer Treatment Trial
Sponsor: Jeremy Keenan, MD, MPH
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kedrion Biopharma, Inc.Program year202513 payments$24,055openpaymentsdata.cms.gov ↗
- Dompe Farmaceutici S.p.A.Program year20255 payments
- Dompe US, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
50.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19%Valacyclovir100%Part D≥14 patientsFluoroquinolone Antibacterial17%Moxifloxacin100%Part D≥22 patients+ 2 more classes in this area
Sensory organs
43.9%Corticosteroid19%Prednisolone Acetate53%Fluorometholone47%Part D≥16 patientsCorticosteroids, plain6.2%Lotemax100%Part D≥11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
5.6%Corticosteroid5.6%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2025–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”